Veltassa®: A Potent Solution for High Potassium Levels
Veltassa offers enduring and well-received potassium regulation for individuals battling chronic kidney disease and chronic heart failure, with global recognition in 41 countries 1-5.
Zeria Pharmaceutical Co., Ltd. Gets the Green Light
The Ministry of Health and Labor Welfare in Japan has given Zeria Pharmaceutical Co., Ltd. the green light to market Veltassa in the Land of the Rising Sun, marking a significant milestone for the company 6.
A Triumph in the East
“We are delighted with Veltassa’s approval in Japan and extend our congratulations to our esteemed partner, Zeria,” shared Hervé Gisserot, General Manager of CSL Vifor. This approval signifies a joint effort to aid the 300,000+ affected by hyperkalemia in Japan, especially those with chronic kidney disease or heart failure. With this stride, a cutting-edge hyperkalemia management therapy is introduced, poised for widespread adoption across diverse patient demographics.
Setting the Stage: The Journey of Approval
The approval was hinged on the comprehensive marketing authorization submission by Zeria, backed by positive clinical data from the Japanese ZG-801 (Veltassa) clinical program for hyperkalemia patients in Japan.
Partnership Pioneering Progress
In 2018, CSL Vifor granted Zeria the exclusive rights to develop and introduce Veltassa in Japan, with plans for the drug to hit the market following National Health Insurance pricing.
A Glance at Hyperkalemia
Hyperkalemia, an urgency demanding attention, results from elevated potassium levels in the bloodstream, raising concerns primarily in patients battling chronic kidney disease (CKD) and heart failure (HF). Medications like renin-angiotensin aldosterone system inhibitors (RAASi), vital in disease management, could heighten the risk of hyperkalemia 10.
Unveiling the Power of Veltassa®
Veltassa boasts sodium-free characteristics, playing a crucial role as a potassium binder that regulates blood potassium levels. Operating within the gastrointestinal tract by trading potassium for calcium, mainly in the colon, Veltassa aids in expelling excess potassium through regular excretion, enabling patients to manage chronic hyperkalemia while adhering to recommended RAASi dosages effectively. Across multiple placebo-controlled, randomized clinical trials, Veltassa has exhibited the optimization of RAASi therapy in a diverse patient pool 2,3,11.
Celebrating a Global Footprint
Today, in September 2024, Veltassa is accessible in 41 nations globally, including the U.S. and the EU, marking a significant step in the treatment of hyperkalemia across the world.
The Unveiling of Veltassa: A Landmark Approval in Japan
Many moons have waxed and waned since the dawn of the 21st century, where the tides of medical research have unfurled new horizons in treating ailments that once seemed unyielding. In this landscape of innovation, a renowned pharmaceutical entity, Vifor International AG (CSL Vifor), has emerged as a stalwart navigator, steering the ship of medical progress in the choppy waters of hyperkalemia. With the recent approval of Veltassa in Japan, the tide of medical history surges forth once more with promise and optimism.
The Clinical Navigation Through History
Rewinding the clock, in a seminal publication in JAMA in 2015, the works of Bakris GL, et al. shed light on the path to understanding hyperkalemia. Their contributions set the stage for the future endeavors that followed suit. Concurrently, Weir MR, et al. in N Engl J Med 2015, embarked on a journey that would eventually culminate in the groundbreaking approval of Veltassa in Japan, marking a significant milestone in the realm of medical therapeutics.
Charting Novel Waters with Veltassa
Venturing further back, in the annals of 2011, Pitt B, et al., penned revelations in the Eur Heart J, laying the groundwork for the understanding of hyperkalemia. Buysse J, et al., in Future Cardiol 2012, continued to deepen the discourse, leading the charge towards innovative treatments for this daunting condition. Fast forward to the present, the recent approval of Veltassa in Japan stands as a testament to the relentless pursuit of medical advancement.
The Ever-evolving Landscape of Medicine
As the sands of time continue to sift through the hourglass of medical history, the research by Weir MR, et al., in the domain of Am J Nephrol. 2024, and Kashihara N, et al., in Kidney Int Rep. 2019, have added brushstrokes to the ever-evolving canvas of hyperkalemia treatment. Montford JR, et al., in J Am Soc Nephrol 2017, and Campese VM, et al., in Kidney Int Suppl 2016, have further enriched the tapestry of knowledge in this field.
Embracing the Future with Veltassa
A phoenix rising from the ashes, the approval of Veltassa in Japan signifies a beacon of hope for patients grappling with hyperkalemia. Through the tireless efforts of researchers like Dunn JD, et al., in Am J Manag Care 2015, and Agarwal R, et al., in Lancet 2019, the medical community stands on the cusp of a new era in the treatment of this condition.
Concluding Thoughts
In the symphony of medical achievements, the approval of Veltassa in Japan resounds as a crescendo that heralds a new dawn in the fight against hyperkalemia. With unwavering dedication and pioneering research, Vifor International AG (CSL Vifor) has etched its name in the annals of medical history, illuminating the path for future breakthroughs that await on the horizon.
CSL Vifor Media Contact
Thomas Hutter
+41 79 957 96 73
[email protected]
View original content to download multimedia:
Veltassa – Approval in Japan
SOURCE Vifor International AG (CSL Vifor)
